	US 11,739,131 B2
	Growth differentiation factor 15 (GDF-15) polypeptides
Yumei Xiong, Palo Alto, CA (US); Yi Zhang, Dublin, CA (US); Jackie Z. Sheng, Thousand Oaks, CA (US); Agnes Eva Hamburger, Newbury Park, CA (US); Murielle M. Veniant-Ellison, Thousand Oaks, CA (US); Grant Shimamoto, Westlake Village, CA (US); Xiaoshan Min, Burlingame, CA (US); Zhulun Wang, Palo Alto, CA (US); Jie Tang, Palo Alto, CA (US); Gunasekaran Kannan, Daly City, CA (US); Kenneth W. Walker, Newbury Park, CA (US); and Bryan Lemon, Mountain View, CA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by Amgen Inc., Thousand Oaks, CA (US)
Filed on May 17, 2019, as Appl. No. 16/416,050.
Application 16/416,050 is a continuation of application No. 15/625,891, filed on Jun. 16, 2017, granted, now 10,336,798.
Application 15/625,891 is a continuation of application No. 14/374,885, granted, now 9,714,276, issued on Jul. 25, 2017, previously published as PCT/US2013/023465, filed on Jan. 28, 2013.
Claims priority of provisional application 61/591,161, filed on Jan. 26, 2012.
Prior Publication US 2019/0315822 A1, Oct. 17, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/475 (2006.01); C07K 14/495 (2006.01); C07K 14/51 (2006.01); A61K 38/16 (2006.01); A61K 38/00 (2006.01); A61K 38/18 (2006.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/475 (2013.01) [A61K 38/00 (2013.01); A61K 38/16 (2013.01); A61K 38/17 (2013.01); A61K 38/18 (2013.01); A61K 39/0005 (2013.01); C07K 14/495 (2013.01); C07K 14/51 (2013.01); A61K 2039/6056 (2013.01); C07K 2319/30 (2013.01)]

6 Claims

1. A dimer comprising:

(A): (I) and (II), wherein

(I) is a fusion protein comprising:

(a) a GDF15 polypeptide comprising an amino acid sequence that is at least 85 percent identical to SEQ ID NO: 4, 8, 12, or 14; and

(b) a negatively charged Fc sequence comprising a charged pair mutation; and

(II) is a second Fc sequence, wherein the second Fc sequence comprises a charged pair mutation and is positively charged;

(B): (III) and (IV), wherein

(III) is a fusion protein comprising:

(a) a GDF15 polypeptide comprising an amino acid sequence that is at least 85 percent identical to SEQ ID NO: 4, 8, 12, or 14; and

(b) a positively charged Fc sequence comprising a charged pair mutation; and

(IV) is a second Fc sequence, wherein the second Fc sequence comprises a charged pair mutation and is negatively charged.